Table 2.
Relationship between methylation status of SPARC gene and clinicopathological characteristics, n (%)
| Parameters | Total, n = 66 |
Methylation status of SPARC |
P value | ||
| U, n = 19 | P, n = 11 | M, n = 36 | |||
| Age in yr | |||||
| < 60 | 21 | 6 (28.6) | 1 (4.8) | 14 (66.7) | 0.178 |
| ≥ 60 | 45 | 13 (28.9) | 10 (22.2) | 22 (48.9) | |
| Gender | |||||
| Male | 51 | 17 (33.3) | 8 (15.7) | 26 (51.0) | 0.323 |
| Female | 15 | 2 (13.3) | 3 (20.0) | 10 (66.7) | |
| Size in cm | |||||
| < 5 | 27 | 6 (22.2) | 6 (22.2) | 15 (55.6) | 0.463 |
| ≥ 5 | 39 | 13 (33.3) | 5 (12.8) | 21 (53.8) | |
| Differentiation | |||||
| Good/moderate | 16 | 6 (37.5) | 4 (25.0) | 6 (37.5) | 0.278 |
| Poor | 50 | 13 (26.0) | 7 (14.0) | 30 (60.0) | |
| Location | |||||
| Upper | 8 | 2 (25.0) | 3 (37.5) | 3 (37.5) | 0.297 |
| Middle | 18 | 6 (33.3) | 4 (22.2) | 8 (44.4) | |
| Lower | 40 | 11 (27.5) | 4 (10.0) | 25 (62.5) | |
| Macroscopic type | |||||
| Borrmann I + II | 19 | 9 (47.4) | 6 (31.6) | 4 (21.1) | 0.002a |
| Borrmann III + IV | 47 | 10 (21.3) | 5 (10.6) | 32 (68.1) | |
| TNM stage | |||||
| I + II | 27 | 14 (51.9) | 8 (29.6) | 5 (18.5) | 0.001a |
| III + IV | 39 | 5 (12.8) | 3 (7.7) | 31 (79.5) | |
| Lymph node metastasis | |||||
| - | 18 | 13 (72.2) | 2 (11.1) | 3 (16.7) | 0.001a |
| + | 48 | 6 (12.5) | 9 (18.8) | 33 (68.8) | |
a
P < 0.05 was considered statistically significant. SPARC: Secreted protein acidic and rich in cysteine.